JavaScript is currently not supported/disabled by this browser. Please enable JavaScript for full functionality.
Loding Loading ....
Home / Proteins & Peptide

Zika Virus Ev2-dimer Protein

BHP20900038
Contact us to order
Tel
+1 866.986.9598
Email
[email protected]
Get a Quote
Request More Infos
Order Now

Credit card payments now incur a 3% fee.

Contact us to order
Tel
+1 866.986.9598
Email
[email protected]
Get a Quote
Ask Merchant
Request More Infos
Sample Request
Target Details Zika virus Ev2 dimer (S2)
Target Pathogen Zika Virus
Shipping 1 week
Description Product Specifications
• Product Name: Zika Virus Ev2-Dimer Protein
• Synonyms: Zika Virus Envelope Protein Dimer, ZIKV E Protein Dimer
• Molecular Weight: Theoretical MW = 89.2 kDa (dimer)
• Tag: His-Tag for simplified purification and detection
• Storage Conditions: Store at -80°C. Avoid repeated freeze-thaw cycles.
• Formulation: Supplied in PBS
• Size: 100 μg
Applications WB
Description Research Applications
  1. Serological Studies:
    Investigating immune responses to the Zika virus (ZIKV) in infected or vaccinated individuals is critical for understanding infection dynamics and vaccine efficacy. The development of envelope protein antigens has enabled differentiation between ZIKV and related flavivirus infections, such as dengue virus, improving diagnostic specificity (Premkumar et al., 2018). Additionally, methods leveraging the Envelope Domain III protein in ELISA have been pivotal in detecting ZIKV-specific IgG antibodies with high precision (Ndiaye et al., 2023).
  2. Antibody Production:
    The development of monoclonal and polyclonal antibodies targeting the ZIKV Envelope protein has played a key role in advancing diagnostic and therapeutic research. For example, production and characterization of envelope domain-specific antibodies have enabled their application in both immunological studies and diagnostics (Akhras et al., 2019). Furthermore, commercial tests based on monoclonal antibodies have improved the reliability and scalability of serological ZIKV diagnostics (Silva et al., 2020).
  3. Diagnostic Assay Development:
    Developing diagnostic assays that utilize the ZIKV Envelope protein as a standard has significantly enhanced the detection and monitoring of ZIKV-specific immune responses. Optimizing production methods for envelope proteins has enabled more reliable ELISA assays, correlating antibody titers with virus neutralization efficacy (Kim et al., 2018). Advances in diagnostic technology have also led to the creation of rapid test kits for detecting IgG/IgM antibodies, facilitating faster and more accurate ZIKV detection in clinical and research contexts (Kim et al., 2018). Additionally, evaluations of commercially available assays provide valuable insights into their diagnostic efficacy and areas for improvement (Low et al., 2021).
  4. Vaccine Research:
    Vaccine research has leveraged the ZIKV Envelope protein as a primary antigen to stimulate potent immune responses. Studies have demonstrated the diagnostic and vaccine potential of envelope protein derivatives, further supporting their role in preclinical vaccine development (Lunardelli et al., 2023). Innovative platforms, such as virus-like particles produced using Pichia pastoris, have facilitated scalable production of envelope proteins for immunological evaluation (Shanmugam et al., 2019). Additionally, the integration of recombinant proteins and monoclonal antibodies into vaccine development pipelines offers promising strategies to enhance immunogenicity and protection (Magalhães et al., 2022).
SKU Supplier No. Size Your price Quantity
BHP20900038 0556-002 100 ug $570.94
Add to Cart